Adaptive Pericardial Sealing Member for Prosthetic Heart Valves

A next-generation prosthetic heart valve system featuring a self-healing, adaptive pericardial sealing member that ensures optimal valve performance and minimizes complications by dynamically responding to changes in the native annulus and patient's physiological environment.

The original patent, 'Pericardial sealing member for prosthetic heart valve', introduced a prosthetic valve with a pericardial sealing member. However, this design has limitations in terms of adaptability to the native annulus and patient-specific factors. The new inventive concept addresses these limitations by introducing a self-healing, adaptive pericardial sealing member that can conform to the unique anatomy of each patient and adapt to changes over time.

The new prosthetic heart valve system comprises a shape-memory alloy stent that can be programmed to conform to the unique anatomy of a patient's native annulus. The pericardial sealing member is enhanced with nanotechnology, promoting tissue regeneration and minimizing inflammation. The system also features a biohybrid pericardial sealing member that incorporates living cells and biomaterials, allowing for real-time monitoring and adaptation to changes in the patient's physiological environment. Additionally, the system includes a sensor-enabled pericardial sealing member that transmits data on valve performance and native annulus geometry, enabling remote monitoring and adjustment through a cloud-based algorithm.

The new claims introduce a paradigm shift in prosthetic heart valve design by incorporating self-healing, adaptive materials and nanotechnology-enhanced tissue regeneration. These features, combined with real-time monitoring and adaptation capabilities, provide a significant improvement over the original patent and existing prosthetic heart valve technologies.

Alternative embodiments of the inventive concept could include the use of different materials or geometries for the shape-memory alloy stent, variations in the nanotechnology-enhanced pericardial sealing member, or alternative sensing technologies for remote monitoring. Additionally, the system could be adapted for use in other implantable devices, such as pacemakers or implantable cardioverter-defibrillators.

The adaptive pericardial sealing member for prosthetic heart valves has significant commercial potential in the medical device industry, particularly in the areas of cardiovascular health and implantable devices. The technology could be licensed to major medical device manufacturers or developed into a proprietary product line, targeting a market projected to reach $1.5 billion by 2025.